SUMMARY. The carbohydrate-deficient glycoprotein (CDG) syndromes (CDGS) are a series of autosomal recessive enzyme deficiencies which result in incomplete glycosylation of plasma proteins. CDGS types Ia and Ib have been related to deficiencies of phosphomannomutase and phosphomannose isomerase, respectively, while CDGS type II results from a deficiency of N-acetylglucosaminyltransferase II. Secondary CDG syndromes are associated with galactosaemia and hereditary fructose intolerance. The diagnosis of CDGS is most easily made by studying the glycoforms of suitable marker proteins using either electrophoresis or is0 electric focusing. This paper reviews the structure of the glycan chains of proteins and structural alterations in CDGS. It also outlines analytical techniques which are useful in the laboratory study of protein glycoforms and the diagnosis of CDGS.
The majority of plasma proteins are glycoconjugates in which one or more carbohydrate chains, or glycans (each consisting of several linked monosaccharides) are covalently linked by glycosidic links to amino acid side chains of the polypeptide. Two types of glycosidic linkages occur between glycans and proteins. Nglycans are linked to the protein through the amide nitrogen atom of an asparagine (Asn) residue, whilst O-glycans are usually connected to the oxygen atom of either a serine (Ser) or a threonine (Thr) residue. Occasionally, O-glycosylation occurs through hydroxylysine or hydroxyproline residues. Many glycoproteins contain only a single type of glycan link but some, including procollagen, glycophorin, and human chorionic gonadotrophin have both types of linkages and are classed as N-, O-glycoproteins.
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It is important to distinguish between glycosylation, in which the oligosaccharyl chains are linked to proteins by a glycosidic link formed by an enzyme-catalysed stereo-specific reaction, and glycation in which carbohydrates react non-enzymatically with primary amine groups to form a Schiff base which then rearranges to give a stable adduct. Glycated proteins represent the chemical equilibrium between the sugar and the protein and examples include HbA lc and glycated albumin. The phenomenon of protein glycation will not be considered further here.
It has been recognized for some time that the glycosylation of proteins has great potential for carrying biological information. Although the precise physiological role of the glycan chains is known for only a few glycoproteins, it is clear that the physiochemical properties of a glycoprotein depend upon both the protein and carbohydrate components, and that synthesis of specific carbohydrate side chains at defined sites is essential for biological functions. Since cells are capable of producing a wide variety of oligosaccharyl structures, sophisticated mechanisms exist to ensure that the correct structures are added to the numerous glycoproteins that are assembled. [1] [2] [3] Alterations in the glycosylation of proteins occur in association with certain diseases, one example being the abnormal fucosylation seen in malignancy." Such changes in protein-bound carbohydrates are secondary to the underlying pathology. There are also examples in which defective glycosylation results from changes in the sequences of amino acids of an individual protein, e.g., (XI-antitrypsin Z.
Primary disorders of N-glycosylation have been identified in only five conditions. These are leukocyte adhesion deficiency type 11,5.6 inclusion body cell disease (I-cell disease)," congenital dyserythropoietic anaemia type 11 8 (previously known as hereditary erythroblastic anaemia with multinuclearity and a positive acid serum lysis test, or HEMPAS), paroxysmal nocturnal haemoglobinuria? and carbohydratedeficient glycoprotein syndromes (CDGS). lO The CDGS and the secondary carbohydratedeficient glycoprotein disorders galact osaemi a and hereditary fructose intolerance form the subject of this review.
GLYCOSYLAnON OF PROTEINS
The co-translational transfer of a common precursor oligosaccharide, Glc, Man5-9
GlcNAc2 (where Glc = glucose, Man = mannose, GlcNAc = N-acetylglucosamine), from a dolichol pyrophosphate lipid carrier to the nascent polypeptide chain initiates the assembly of Nlinked glycans (Fig. 1 ).11 13 This step is catalysed by an oligosaccharyltransferase in the lumen of the rough endoplasmic reticulum," which transfers the precursor glycan en bloc to an asparagine residue within the recognition tripeptide Asn-X{Ser/Thr/Cys), where X = any amino acid other than proline or aspartic acid and Cys = cysteine. Not all of the consensus sequences in glycoproteins are necessarily glycosylated. Since all newly synthesized glycoproteins pass through the same assembly pathway and are thus exposed to the same transferases, it is probable that the conformation of the growing polypeptide chain determines whether a particular site is glycosylated. Once the precursor glycan has been attached to the polypeptide chain it is then subjected to trimming by several glycosidases, each removing a specific monosaccharyl residue. Middle-stage processing then takes place, involving elongation of the processed oligosaccharides by the addition of new glycoside residues. Finally, late-stage processing involves further elongation of the glycan chains, sometimes with additional modifications such as sulphation or phosphorylation.
As a consequence of the processing pathways the N-glycans of mature glycoproteins all have a common invariant core which is composed of three D-mannose and two N-acetyl-galactosamine residues. Additional monosaccharide units are attached to this core and allow the glycan chains to be grouped into high mannose, complex, hybrid and poly-N-acetyllactosamine types (Fig. 2) .
It should be noted that the glycosylation pathway is not template-based, i.e., geared towards the mass production of invariant structures. The glycosylation 'fingerprint' or glycotype of an individual cell depends upon the concentrations and substrate specificities of the glycosidases and glycosyltransferases that are expressed in that individual cell. The expression of these processing enzymes can vary with the physiological or pathological state of the cells, and vary between individual cells in the same state. Furthermore, the nature of the glycan structure at a particular glycosylation site will depend upon which processing enzymes recognize it as a substrate. This can vary from site to site within an individual polypeptide as well as between the potential glycosylation sites on different polypeptides. Finally, the glycan structures at any given glycosylation site may show micro heterogeneity as a consequence of subtle conformational difference existing within the individual monosaccharide units which make up the glycans.
Any individual glycoprotein molecule therefore has a glycan structure that is only one of a range of possible glycan structures associated with that specific protein. The overall spectrum of glycoforms found for a particular glycoprotein is often species-and tissue-specific. Furthermore, the range of glycoforms produced for a particular glycoprotein may change during the normal development of tissues, as well as varying as a consequence of pathological processes.
GLYCAN STRUCTURE OF SERUM TRANSFERRIN
Transferrin is a useful model glycoprotein, and one that is pivotal to the diagnosis of the carbohydrate-deficient glycoprotein syndromes. , DoI-P-P which, since it carries a negative charge, contributes to the overall charge on the glycoprotein (Fig. 3) . The degree of sialylation thus influences the electrophoretic behaviour of transferrin and it is possible to separate the component glycoforms using a suitable technique. I?
The antennary form of the glycan occupying a particular glycosylation site on transferrin varies, and the permutations explain much of the observed heterogeneity of serum transferrin.
Approximately 85% of the transferrin in normal serum is in the tetra-sialyl form, with four sialic acid residues probably present as two biantennary structures. Penta-sialyl and tri-sialyl forms make up most of the remainder. Only trivial amounts of transferrin containing fewer than three sialic acid residues are seen in normal serum and this can be explained by the removal of underglycosylated transferrin from the circulation by the asialoglycoprotein receptor.lv'" 
PRIMARY CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROMES
In the late 1970s a pair of monozygotic twins were reported as having developmental delay in association with endocrine and biochemical abnormalities.
2o • 2 1 These children were later found to have unusual patterns of serum transferrin on isoelectric focusing, and partial deficiencies of protein-bound sialic acid, galactose and N-acetylglucosamine were identified.F As further cases were investigated it became apparent that this hypoglycosylation affected many, possibly all, plasma glycoproteins.Pv" It seemed likely, therefore, that these patients had a disorder primarily affecting protein glycosylation. 25 -28 As a result of the characteristic partial deficiency of several carbohydrates from glycoproteins, the term carbohydrate-deficient glycoprotein syndrome is used to describe these conditions.
On the basis of clinical and laboratory findings, five types of COGS have so far been reported. It is also recognized that other inborn errors of carbohydrate metabolism, such as galactosaemia and hereditary fructose intolerance, also give rise to carbohydrate-deficient glycoproteins. Collectively, the conditions offer important insights into the metabolic control of the glycosylation pathway.
For historical reasons the classification of COGS is based upon the glycoform pattern observed for transferrin. COGS type Ia and type Ib give transferrin glycoform patterns which are indistinguishable. The subtypes differ in the nature of the enzyme deficiency; type Ia is due to a deficiency of the enzyme phosphomannoAnn Clin Biochem 1999: 36 mutase (PMM), while type Ib is associated with a deficiency of phosphomannose isomerase (PMI). These two subtypes may also differ in clinical presentation, although at the time of writing only one patient with type Ia had been described in the literature, with a report on a further four cases awaited.
CDGS TYPE I
Clinical aspects Infants with COGS type Ia have subtle abnormalities at birth.
-
3 1 These include an antimongoloid slant to the eyes; abnormal fat pads, particularly on the upper outer aspect of the buttocks; peau d'orange skin on the legs; long fingers and toes; and limited movement of the hips and knees. They fail to thrive from birth and by 6 weeks roving eye movements and marked head lag on pulling to sit are often evident. Ascites may appear in the neonatal period; the liver size is normal or modestly increased. The infants are prone to accumulate fluid in the pericardial and pleural cavities and may present with tamponade. Cardiac failure can also be due to cardiomyopathy.P'P Proteinuria is common, although the nephrotic syndrome is unusual.r'r" The kidneys are large and cysts may be demonstrated by ultrasound. Affected infants are also prone to stroke-like episodes and periods of stupor. Bruising and intracranial haemorrhage have been described. Opportunistic infections have been documented in a few infants. There is a high mortality in infancy amongst the most severely affected patients. 46 ,47 CDGS type I is therefore a deficiency in glycosylation site occupancy. Since up to 50% of the transferrin in affected individuals is glycosylated normally, the condition is one of a relative deficiency and not a total lack of glycosylation ability (Fig. 4) , which points to a defect in the early steps of glycosylation (probably resulting from a lack Molecular biology of CDGS I Structural studies using nuclear magnetic resonance and mass spectroscopy reveal that the carbohydrate deficiency in transferrin is not restricted to the sialic acid residues and that some transferrin molecules are missing complete In the survivors, developmental delay becomes apparent during the first year of life. The truncal hypotonia is associated with ataxia, which makes walking very difficult for these children. Some patients have acquired microcephaly. An alternating convergent squint is common. Neurological imaging shows marked atrophy of the cerebellum (and sometimes of the brain stem) and there may be a substantial collection of fluid in the posterior fossa, suggestive of a Dandy-Walker cySt. 31 ,36-39 During childhood the lower limb tendon reflexes are lost and a neuropathy can be detected on electromyoneurography. Stroke-like episodes can also occur. A pigmentary retinopathy can often be detected, often associated with abnormalities on electroretinography.P'P although none of the patients has developed blindness as a result. Kyphoscoliosis and pectus carinatum become apparent and this, together with incomplete extension at the hips and knees, give the children a very hunched appearance. Linear growth is retarded."
During teenage years the children continue to make developmental progress, albeit remaining significantly delayed (IQ approximately 50-60). They are extrovert and their understanding is better than their gross motor and expressive skills. Most manage to communicate reasonably well despite dysarthria. Motor neuron weakness in lower limbs progresses and is associated with atrophy of the lower legs. Female patients generally fail to develop secondary sexual characteristics due to primary ovarian failure." although pubertal development has been observed." Males do undergo puberty with the development of secondary sexual signs, but many have a low serum testosterone concentration with either normal or only slightly raised gonadotrophin concentrations as well as testicular atrophy. In adult life, signs of premature aging can become obvious.
Systematic prevalence studies of CDGS type I have not yet been published, but preliminary estimates of prevalence are in the region of 1/40000 to 1/60000. Overall mortality is around 15%, with a median age at death of 2·2 years (range 1 week to II years).
of the dolichopyrophosphate oligosaccharide precursor or in its transfer on to the nascent peptidej.t" A supply problem is most likely as there is decreased incorporation of [3Hjmannose into both N-linked oligo saccharides and their lipid precursors in the fibroblasts of patients with CDGS type 1,49 while the activity of the transfer enzyme, N-oligosaccharyltransferase, is normal in fibroblasts. 50 It has been shown that there is marked reduction in the activity of PMM in the fibroblasts of CDGS type la patients. 51 PMM catalyses the interconversion of mannose-6-phosphate and mannose-I-phosphate (Fig. 5) . A deficiency would be expected to reduce availability of mannose-I-phosphate and, thus, the GDP-mannose needed for the synthesis of dolicholpyrophosphate-oligosaccharides. Supplying mannose, but not glucose, to CDGS type la fibroblasts in culture in part corrects the altered glycosylation.F This is somewhat surprising, since the bulk of the endogenous mannose required for glycoprotein synthesis is assumed to be derived from glucose by the action of phosphomannose isomerase, and the activities of this enzyme, as well as that of hexokinase and phosphoglucose isomerase, have been shown to be normal in CDGS type la. 53 This implies that glucose is not the predominant source of mannose for glycoprotein synthesis, but rather that mannose is more directly required.
Although supplying mannose to CDGS cells in culture improves their glycoprotein synthesis, and oral ingestion of mannose increases its blood levels;" it is unlikely that this will prove a suitable therapeutic approach for CDGS type la.
Alternative explanations for the CDGS type I phenotype include a deficiency of dehydrodolichol reductase activity. 55 This argument is based upon the observation that patients with CDGS type la retain between 10 and 45% of their PMM activity, which should be sufficient to cope with the demands for mannose-Iphosphate made by the cell; furthermore, PMM-deficient cells should accumulate (GlcNAc)rpyrophosphate-dolichol, yet this is not found. Phosphoglucomutase is capable of catalysing the conversion of mannose-6-phosphate to mannose-I-phosphate in vitro and, while the importance of this reaction in vivo is not known, the possibility of phosphoglucomutase acting as some form of salvage pathway should not be discounted. It has also been shown that alkaline phosphatase in the serum of patients with CDGS I lacks the glycan chain derived from the glycosylphosphatidylinositol (GPI) anchor. 56,57 This may reflect a deficiency of dolichylphosphomannose, a substrate used for glycan formation of the GPI anchor.
Genetics of CDGS type Ia CDGS type fa is inherited as an autosomal recessive trait." The incidence of the disease is not yet known, but more than 200 patients have been identified from more than 14 countries.
Phosphomannomutase genes are present on two chromosomes. The PMMI gene is on chromosome 22qI3,59.6o with a second PMM gene (PMM2) located on chromosome l6p13. The PMM2 gene encodes a protein which is 66% homologous to that of PMMl. 61 Eleven out of sixteen cases of CDGS I studied were found to have mis-sense mutations in the PMM2 gene, all of which had a reduced PMM enzyme activity.
Linkage analysis maps the CDGS gene to chromosome region 16pI3.3-pI3.l2. 62 64 Of 17 families sharing a particular haplotype, 15 came from the same region of southwest Sweden, southern Norway and eastern Denmark, suggesting that they share a common ancestral CDGS I mutation. By contrast, studies in other nonScandinavian families suggest multiple founder effects, with various spontaneous mutations occurring in separate geographical locations.
Laboratory aspects
The clinical biochemistry is dominated by abnormalities of N-glycosylation of numerous plasma glycoproteins.Pr'" including transferrin. An additional common finding is hypoalbuminaemia. While proteinuria is a common feature, nephrotic syndrome and renal failure are not typical and it is unlikely that the observed hypoalbuminaemia can totally be explained by circulatory loss.
The concentrations of a wide range of clotting factors and their inhibitors are decreased in blood, particularly factors II, V, X, XI, antithrombin and protein C, while levels of fibrinogen D-dimer are frequently increased." Either of these effects could give rise to coagulopathies which may contribute to the stroke-like episodes that are observed in cases of CDGS. Coagulation screening assays, such as the activated partial thromboplastin time (APTT) and prothrombin time (PT) are often normal, so analysis of individual coagulation factors is recommended.t" particularly when there are clinical symptoms or if liver biopsy or elective surgery is being considered.
Thyroxine-binding globulin (TBG) concentrations are low in about 75% of cases. In many cases of CDGS total plasma thyroxine (T 4 ) , triiodothyronine (T 3 ) and reverse T 3 (rT 3 ) concentrations are subnormal, often disproportionate to the TBG level. 67 The finding of unexplained neonatal hypothyroidism or a biochemically euthyroid state with low TBG should prompt investigation for CDGS.
Cases of CDGS have also been described with other biochemical findings, including non-ketotic hyperglycinaernia.f" and with isolated, unexplained increases in blood lysosomal enzymes, particularly p-hexosaminidase.
COGS TYPE IB
About 20% of patients with transferrin glycoform patterns typical of CDGS type I have no reduction in fibroblast PMM activity.s? A deficiency in PMI 70 may explain some of these cases. CDGS type I associated with a deficiency in PMI has been classed as CDGS type lb.
Molecular biology of COGS type Ib
In the one case so far reported CDGS type Ib is caused by a genetic defect in the PMIl gene. PMI deficiency reduces the production of mannose-6-phosphate from fructose-6-phosphate (Fig. 5) . The transferrin glycoform patterns of CDGS types Ia and Ib are identical, and enzyme studies are necessary to distinguish the two conditions. The use of oral mannose in CDGS type Ib is more successful and leads to a considerable improvement in the patterns of protein glycoforms. Care has to be taken, however, to prevent mannose toxicity."
The reasons for the difference in clinical phenotype between CDGS types Ia and Ib are not yet clear, but could be related to the fact that mannose uptake from both mannose and glucose are blocked in PMM deficiency, whereas the uptake of exogenous mannose is unaffected in PMI deficiency (Fig. 5 ). This could also explain the difference in response of these two conditions to oral mannose.
COGS TYPE II
Clinical aspects This condition has so far been described in two children from unrelated families. The first was a 3-year-old Iranian girl born of consanguineous parents.F the other a Belgian boy." In contrast to CDGS I, the patients had more severe psychomotor retardation but a normal cerebellum on magnetic resonance imaging (MRI) scan and no peripheral neuropathy. Some dysmorphic features were present, including large, dysplastic, posteriorly rotated ears, thoracic deformity, widely spaced nipples, dystrophic limbs and proximally implanted thumbs. Both cases had stereotypic handwashing movements and ventricular septal defects, osteopenia and hypogonadism.
Molecular biology
Nuclear magnetic resonance analysis and electrospray mass spectrometry of purified CDGS type II transferrin show that its glycan chains consist primarily of truncated, mono-antennary, monosialylated N-glycans (Fig. 6) . The difference in molecular weights between normal transferrin and the disialotransferrin of the patients indicate two moles of the antennary chain oc-NAcNeu (2 ...... 6)p-D-Gal(I ...... 4)P-D-GlcNAc (where Gal = galactose) to be missing, consistent with a deficiency in N-acetylglucosaminyltransferase II (GlcNAcT-II). The attachment of antennae to the common (Man)3(GlcNAch-Asn core structure is initiated by the sequential action of six Nacetylglucosaminyltransferases (numbered GlcNAcT-I to GlcNAcT-VI). Prior action of GlcNAcT-I is essential for the actions of GlcNAcT-II, -III and -IV, while action of GlcNAcT-II is required prior to that of GlcNAcT-V. Synthesis of complex N-glycans cannot occur until after both GlcNAcT-I and GlcNAcT-II have acted. Patients lacking GlcNAcT-II activity are therefore unable to attach GlcNAc residues in the ocl ...... 6 position of the core, resulting in incomplete structures.
A deficiency of GlcNAcT-II was confirmed in fibroblasts which showed a marked reduction in activity to approximately I % that of normal.?" Adding GlcNAcT-II from normal fibroblasts to extracts of patients' fibroblasts replaced the missing activity and indicated that the deficient activity in the patient was not due to the presence of an enzyme inhibitor. Blood relatives of patients have been shown to have GlcNAcT-II activities between 32 and 67% of normal, consistent with an autosomal recessive disease." Laboratory aspects Proteinuria was absent, with normal serum albumin and glutamic pyruvate transaminase activity. Coagulopathies due to deficiencies of clotting factors IX, XI, XII, antithrombin III, protein C, protein S and heparin cofactor II were found. The serum activity of P-glucuronidase was reduced. Again, the most characteristic feature was the transferrin glycoform pattern. The normal tetra-sialo transferrin band was completely absent and was substituted by a heavy band corresponding to disialo-transferrin. Total serum transferrin concentrations were normal.
CDGS TYPE III
Clinical aspects This has been described in two children of unrelated families." One girl was a 9-year-old from Sweden, the other a 2-year-old from Germany. Both patients displayed perinatal floppiness, a slightly dystrophic appearance, severe psychomotor retardation, tetraparesis, infantile spasms, optic atrophy, depigrnented skin and hepatomegaly. In early infancy the hypotonia was associated with brisk tendon reflexes, but later the flaccid tetraparesis was associated with absent reflexes. Central and cortical atrophy and generalized dysmyelination were apparent on computed tomography and MRI. In one case hypoplasia of the corpus callosum and a Dandy-Walker cyst were present. Cortical evoked potentials were severely abnormal from early infancy.
Laboratory aspects Intermittent elevation of liver enzyme concentration was detected. Cerebrospinal fluid (CSF) protein concentrations were not elevated, and the levels of albumin and other proteins in the plasma were normal. Although increased levels of carbohydrate-deficient transferrin were found using chromatographic methods, isoelectric focusing patterns revealed only a slight increase 
CDGS TYPE IV

Clinical aspects
The only two cases so far reported"? are a girl of Turkish descent and a German boy. Both showed microcephaly with severe epilepsy and absent psychomotor development. Dysmorphic features included adducted thumbs, a high arched palate and posteriorly rotated, dysplastic ears. One of the infants had multiple contractures, the other had optic atrophy and a coloboma of the iris. Muscle tone was strikingly abnormal but varied from hypotonicity to hypertonicity. In one patient MRI showed atrophy of the cerebrum and corpus callosum; in the other the cerebellum was atrophied more than the cerebrum. Generalized clonic-tonic seizures and myoclonic fits were observed and in both cases the electro-encephalograph (EEG) showed hypsarrthymia.
Laboratory aspects Routine biochemistry of blood and CSF was generally unremarkable, with only slight reductions in the plasma concentrations of antithrombin III and apolipoprotein B. TBG and albumin concentrations were both within the normal range. Quantitative determination of serum carbohydrate-deficient transferrin shows moderately elevated values. Isoelectric focusing revealed the absence of the asialo-transferrin band typically seen in CDGS type I, with an increase in disialo-transferrin, which is less than that found in CDGS type I and different also from that of types II and III.
LABORATORY METHODS IN DETECTION OF CDGS
The laboratory diagnosis of COGS rests on two observations: I the detection of charge heterogeneity within individual glycoproteins, and 2 the demonstration that this charge heterogeneity is a function of glycan side-chain structure.
One corollary of these observations is that the charge heterogeneity cannot be due to difference in the primary sequence of amino acids of the protein, i.e., a sequence polymorphism. The critical step, therefore, is to exclude amino acid substitutions as an explanation of charge heterogeneity. Once the nature of the glycoprotein abnormality has been established, appropriate enzyme activities can then be measured.
Detecting charge heterogeneity Detecting charge isoforms of proteins is straightforward and glycoforms of transferrin have been resolved using techniques including isoelectric focusing.P acrylamide gel electrophoresis.I? twodimensional electrophoresis.i" chromato graphy,81 capillary electrophoresis'S and sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).83 One convenient approach involves agarose electrophoresis with nitrocellulose immunoblotting (Figs 7 and 8 ). The common CI and C2 phenotypes are not resolved by this technique, but many other phenotypic variants are. Double, slow-moving or absent transferrin bands which are found following serum electrophoresis should always be investigated for glycan abnormalities, although an apparently normal transferrin band does not exclude CDGS. Quantitative measurement is also unreliable, as the total concentration of transferrin is often normal.
CSF is an ideal reference material for use in any method since it contains a natural mixture of transferrin glycoforms having from zero to six sialic acids (inclusive). Serum, by contrast, contains only trivial amounts of transferrins having fewer than three sialic acids residues. We routinely include normal CSF and serum on each electrophoresis run.
Proving glycan structure The cornerstone of diagnosing COGS is to show that any charge heterogeneity observed results from alterations in glycan chain structure. This is easily demonstrated by using electrophoresis to detect the change in the overall charge of the transferrin that occurs when all the sialic acid residues are enzymatically removed (Fig. 9) . As sialic acid is the only monosaccharide that contributes to the overall charge of the molecule, when all sialic acids are removed the only charge left is that intrinsic to the polypeptide chain. Removing the sialic acid residues therefore reduces all glycoforms to the asialo-protein. galactosaemia should be excluded before a diagnosis of COGS is made. The glycosylation defect in galactosaemia is a secondary feature. and within 1-2 weeks of starting a galactose-free diet the transferrin glycoform pattern reverts to normal (Figs 10 and II) .
From the accumulated experience of over 20 years of neonatal screening for galactosaemia it has become apparent that even the earliest and most careful dietary restriction does not prevent all chronic complications of this disorder. Even well-managed galactosaemic patients develop a long-term encephalopathic syndrome characterized by delayed development, declining IQ with age, speech deficiency and personality disorders. Galactosaemia also gives rise to a pattern of serum transferrin glycoforms that is indistinguishable from that seen in COGS type I. and
The transferrin glycoform pattern characteristic of COGS type I is not restricted to this condition. Other inborn errors of carbohydrate metabolism give rise to similar abnormalities and need to be excluded from the different diagnosis.
SECONDARY COGS
p-glucuronidase in amniotic fluid are additional features useful to support a diagnosis." One promising approach is to measure PMM activity in either cultured amniocytes or chorionic villus cells." although this is applicable only to foetuses which are PMM-deficient. Owing to residual PMM activity it is essential that enzyme studies be supported by genetic linkage analysis to confirm involvement of the PMM2locus. In due course, diagnosis will be possible by detection of specific mutations in the PMM2 gene."
Keir et 01. cortical neuronal degeneration and atrophy of the cerebellum and basal ganglia. Most patients with galactosaemia, even those with good dietary control, display persistent increases in red cell galactose-I-phosphate concentration and urinary galactitol excretion. This has traditionally been explained either by dietary non-compliance or by cryptic sources of galactose, such as fruit and vegetables. However, it would appear that both normal adults and adults with galactosaemia are capable of synthesizing more than I g of galactose per day. 92 In the face of this amount of endogenous galactose production, dietary manipulation is likely to have only a small influence and the implications of this on long-term complications need to be investigated. Although the serum protein glycoform pattern appears to normalize with dietary treatment, the possibility of subtle glycosylation problems remains. For example, there is evidence for a reduction in glycolipids containing galactose, with a concomitant increase of their precursors in the brain."
The nature of the metabolic block in protein glycosylation seen in galactosaemia is uncertain; however, structural studies have shown that the glycan side chain of transferrin lacks both sialic acid and galactose." Since galactose is the penultimate monosaccharide on the glycan chain, it is tempting to suggest that the accumulation of galactose-I-phosphate either prevents the incorporation of galactose into the structure, as this normally involves a PI, 4 linkage, or that there is a deficiency of the donor molecule uridine diphosphate (UDP)-galactose.
Ann Clin Biochem 1999: 36
In either case the absence of a galactose residue means that there is no substrate for the terminal sialic acid to attach to. As with COOS type I, about half of the serum transferrin is glycosylated normally, suggesting that some UDPgalactose is available, probably through epimerization of UDP-glucose. There are nevertheless differences between the glycan patterns for lysosomal enzymes seen in galactosaemia compared with COOS I, which may indicate that the metabolic block is different in the two conditions.
Hereditary fructose intolerance Hereditary fructose intolerance (HFI) is an autosomal recessive disorder resulting from a deficiency of fructose-I-phosphate aldolase. Untreated cases of HFI show patterns of serum transferrin glycoforms which are indistinguishable from those of CDGS type 11. 95 HFI results in an accumulation of fructose-l-phosphate and this has been shown to inhibit PMM. 96 It is therefore likely that in HFI there is an inhibition of an early step in the N-glycosylation pathway, causing the same or similar underglycosylation of proteins as is seen in COOS type I. A major difference from CDGS type I is that in HFI the error in the glycosylation pathway may prove to be limited to those tissues possessing the fructose pathway, principally the liver, kidney and small intestine.
